OGEN

Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It focuses on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its other product candidate, ONP-001, is in its early stage and clinical trials.

Wall Street analysts forecast OGEN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for OGEN is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Oragenics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Oragenics Inc. EPS for the last quarter amounts to -1.96 USD, decreased -82.69 % YoY.

Oragenics Inc (OGEN) has 3 emplpoyees as of December 16 2025.

Today OGEN has the market capitalization of 3.49M USD.